rofecoxib has been researched along with Cognition Disorders in 11 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We summarize how the sponsor represented mortality findings associated with rofecoxib in clinical trials of patients with Alzheimer disease or cognitive impairment." | 7.74 | Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. ( Kronmal, RA; Psaty, BM, 2008) |
| " We summarize how the sponsor represented mortality findings associated with rofecoxib in clinical trials of patients with Alzheimer disease or cognitive impairment." | 3.74 | Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. ( Kronmal, RA; Psaty, BM, 2008) |
| "Forty two had progressed to Alzheimer type dementia during a five year follow up period and were considered to have predementia Alzheimer's disease at baseline." | 2.71 | Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? ( Scheltens, P; Verhey, FR; Visser, PJ, 2005) |
| "Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species." | 1.39 | Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. ( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013) |
| "Rofecoxib is a selective cyclooxygenase 2 enzymes belongs to non-steroidal anti-inflammatory drug, commonly called as coxibs." | 1.37 | Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat. ( Kumar, A; Pahwa, D; Prakash, A, 2011) |
| " Chronic administration of NSAIDs at the ED(50) doses (nimesulide, rofecoxib and naproxen for 15 days) significantly reversed the age or scopolamine-induced retention deficits in both test paradigms." | 1.31 | Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. ( Jain, NK; Kulkarni, SK; Patil, CS; Singh, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 3 |
| Sharma, N | 1 |
| Mishra, J | 2 |
| Kalonia, H | 1 |
| Prakash, A | 2 |
| Pahwa, D | 2 |
| Jain, NK | 1 |
| Patil, CS | 1 |
| Kulkarni, SK | 1 |
| Singh, A | 1 |
| Ashton, D | 1 |
| Kim, P | 1 |
| Griffiths, N | 1 |
| Beran, R | 1 |
| Thal, LJ | 2 |
| Ferris, SH | 2 |
| Kirby, L | 1 |
| Block, GA | 1 |
| Lines, CR | 2 |
| Yuen, E | 1 |
| Assaid, C | 2 |
| Nessly, ML | 2 |
| Norman, BA | 2 |
| Baranak, CC | 1 |
| Reines, SA | 1 |
| Visser, PJ | 1 |
| Scheltens, P | 1 |
| Verhey, FR | 1 |
| Jelic, V | 1 |
| Kivipelto, M | 1 |
| Winblad, B | 1 |
| Ownby, RL | 1 |
| Aisen, PS | 1 |
| Giuliani, MJ | 1 |
| Potter, WZ | 1 |
| Psaty, BM | 1 |
| Kronmal, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)[NCT00567060] | 676 participants (Actual) | Interventional | 2000-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for rofecoxib and Cognition Disorders
| Article | Year |
|---|---|
Clinical trials in mild cognitive impairment: lessons for the future.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Top | 2006 |
4 trials available for rofecoxib and Cognition Disorders
| Article | Year |
|---|---|
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Topics: Aged; Cognition Disorders; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2005 |
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase | 2005 |
Rofecoxib in mild cognitive impairment.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Disea | 2006 |
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cognition Disorders; Cyclooxygenase 2 In | 2008 |
6 other studies available for rofecoxib and Cognition Disorders
| Article | Year |
|---|---|
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Caffeic Acids; Cognition Disorders; Dise | 2011 |
Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats.
Topics: Acetates; Acetylcholinesterase; Animals; Antioxidants; Caffeic Acids; Cognition Disorders; Cyclooxyg | 2012 |
Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice.
Topics: Aging; Animals; Anxiety; Avoidance Learning; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2 | 2002 |
Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.
Topics: Aged; Chronic Disease; Cognition Disorders; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lactones; | 2004 |
Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
Topics: Alzheimer Disease; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Cognition D | 2008 |